Today: 7 February 2026
Subscribe
Browse Category

Pfizer News 31 December 2025 - 5 February 2026

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
····
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer shares rose 0.7% to $25.84 in Monday afternoon trading, tracking a broader U.S. stock rally ahead of major earnings and a Federal Reserve policy decision. Investors are watching for Pfizer’s Feb. 3 earnings and updates on its 2026 outlook, as the company faces falling COVID demand and looming patent expirations. Trading volume remained moderate, with no major company news released.
26 January 2026
·····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
·····
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

New York, Jan 13, 2026, 15:07 EST — Regular session. Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session. The selling comes as CEO Albert Bourla pushes to sharpen Pfizer’s post-COVID growth narrative and justify its spending on new drugs. At Monday’s J.P. Morgan Healthcare Conference, Bourla likened the potential consumer demand for obesity meds to the early surge in Viagra sales and admitted Pfizer underestimated how quickly the “cash-pay” market—patients paying out of
13 January 2026
····
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

New York, Jan 13, 2026, 10:50 (EST) — Regular session Pfizer Inc (PFE) shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029. (Reuters) The obesity market has turned into a fierce arena for deals and capital spending
13 January 2026
·····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

NEW YORK, Jan 3, 2026, 15:55 ET — Market closed Pfizer Inc (NYSE: PFE) shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday. The stock is starting 2026 with drug pricing back in focus, a recurring risk for big pharma that can weigh on sentiment. Drugmakers raised U.S. list prices on at least 350 branded medicines starting Jan. 1, with Pfizer leading with increases on about 80 drugs, including a 15% hike for its COVID vaccine Comirnaty, a report said. Becker’s Hospital Review The pricing debate lands as
3 January 2026
·····
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome,
2 January 2026
·····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 06:48 ET — Market closed Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday. (Reuters) Why it matters now: January is the industry’s main reset point for annual drug pricing, and the moves land as Washington keeps drug costs in the political crosshairs. Investors often read fresh price actions as both a revenue lever and a regulatory risk flag. The headline
1 January 2026
·····
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters The timing
1 January 2026
·····
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration presses the industry to lower costs. Annual list-price resets can also shape negotiations with insurers and the political risk premium investors apply to large drugmakers. Pfizer’s own outlook has put a spotlight on revenue durability. In its December guidance, Pfizer
31 December 2025
·····
1 2 3

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Go toTop